1241. In vitro Activity of Ceftaroline Against Pathogens Collected Globally from the AWARE Surveillance Program, 2016
Session: Poster Abstract Session: Expanded Spectrum - New Antimicrobial Susceptibility Testing
Friday, October 6, 2017
Room: Poster Hall CD
Posters
  • Pfizer_P96_CPT_global_IDSA 2017_Final.pdf (717.5 kB)
  • Background: Ceftaroline, the active metabolite of ceftaroline fosamil, is a cephalosporin developed for treating infections caused by Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA), Streptococcus pneumoniae, β-hemolytic streptococci, and some Gram-negative pathogens. This study reports the in vitro activity of ceftaroline against clinically relevant isolates collected in 2016 from the AWARE Surveillance Program.

    Methods: 22,752 non-duplicate methicillin-sensitive S. aureus (MSSA), MRSA, S. pneumoniae, beta-hemolytic streptococci (S. pyogenes, S. agalactiae, S. dysgalactiae) Haemophilus influenzae, and extended spectrum β-lactamase (ESBL)-negative Enterobacteriaceae were collected from (n/%) Asia/South Pacific (4,215/18.5%), Europe (12,962/57.0%), Latin America (3,384/14.9%), and Middle East/Africa (2,191/9.6%) during 2016. Isolates were from (n/%) complicated intraabdominal (2,149/9.5%), complicated urinary tract (3,029/13.3%), complicated skin and skin structure (8,271/36.4%), blood stream (2,422/10.6%) and lower respiratory tract infections (6,881/30.2%). MIC values were determined by broth microdilution and interpreted using CLSI breakpoints.

    Results: Ceftaroline activity, based on % susceptibility (%S) and MIC90, is shown in the table. Ceftaroline was active in vitro against both Gram-positive (100% of MSSA, 93.6% of MRSA and 99.7% of S. pneumoniae) and Gram-negative (99.7% of H. influenzae and 91.7% of ESBL-negative Enterobacteriaceae) isolates.

    Organism (N)

    % S

    % I

    % R

    MIC50

    MIC90

    MRSA (5,022)

    93.6

    6.0

    0.5

    0.5

    1

    MSSA (3,675)

    100

    0

    0

    0.25

    0.25

    Streptococcus pneumoniae (2,024)

    99.7

    --

    0.3

    0.008

    0.12

    Beta-hemolytic streptococci (1,713)

    100

    --

    --

    0.008

    0.015

    Enterobacteriaceae, ESBL-Negative (9,647)

    91.7

    3.7

    4.6

    0.12

    0.5

    Haemophilus influenzae (671)

    99.7

    --

    0.3

    ≤0.015

    0.03

    %S, %I, %R- percent susceptible, intermediate, resistant based on CLSI breakpoints; MIC50, MIC90 in µg/mL

    Conclusion: Based on these data generated with isolates collected in 2016, ceftaroline exhibited potent in vitro activity against clinically relevant isolates, with >91% of all isolates susceptible at their CLSI breakpoints.

    Funding: This study was sponsored by AstraZeneca. The AstraZeneca product ceftaroline fosamil was acquired by Pfizer in December 2016.

    Meredith Hackel, PhD, MPH1, Joseph Iaconis, PhD2 and Dan Sahm, PhD1, (1)International Health Management Associates, Inc., Schaumburg, IL, (2)AstraZeneca Pharmaceuticals, Waltham, MA

    Disclosures:

    M. Hackel, None

    J. Iaconis, AstraZeneca: Employee and Shareholder , Salary and Shareholder in AstraZeneca

    D. Sahm, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.